The DOI matches its Crossref record; 86 of the 86 references it cites were found in a registry or an index.
Drug resistance in epilepsy
Abstract
Drug resistance is estimated to affect about a third of individuals with epilepsy, but its prevalence differs in relation to the epilepsy syndrome, the cause of epilepsy, and other factors such as age of seizure onset and presence of associated neurological deficits. Although drug-resistant epilepsy is not synonymous with unresponsiveness to any drug treatment, the probability of achieving seizure freedom on a newly tried medication decreases with increasing number of previously failed treatments. After two appropriately used antiseizure medications have failed to control seizures, individuals should be referred whenever possible to a comprehensive epilepsy centre for diagnostic re-evaluation and targeted management. The feasibility of epilepsy surgery and other treatments, including those targeting the cause of epilepsy, should be considered early after diagnosis. Substantial evidence indicates that a delay in identifying an effective treatment can adversely affect ultimate outcome and carry an increased risk of cognitive disability, other comorbidities, and premature mortality. Research on mechanisms of drug resistance and novel therapeutics is progressing rapidly, and potentially improved treatments, including those targeting disease modification, are on the horizon.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Kwan, P., Arzimanoglou, A., Berg, A. T., Brodie, M. J., Allen Hauser, W., Mathern, G., Moshé, S. L., Perucca, E., Wiebe, S., & French, J. (2010) · Epilepsia · doi:10.1111/j.1528-1167.2009.02397.x · Cited by 4,877
Self-citationA Randomized, Controlled Trial of Surgery for Temporal-Lobe Epilepsy
Wiebe, S., Blume, W. T., Girvin, J. P., & Eliasziw, M. (2001) · New England Journal of Medicine · doi:10.1056/nejm200108023450501 · Cited by 3,525
Chen, Z., Brodie, M. J., Liew, D., & Kwan, P. (2018) · JAMA Neurology · doi:10.1001/jamaneurol.2017.3949 · Cited by 1,514
Specchio, N., Wirrell, E. C., Scheffer, I. E., Nabbout, R., Riney, K., Samia, P., Guerreiro, M., Gwer, S., Zuberi, S. M., Wilmshurst, J. M., et al. (2022) · Epilepsia · doi:10.1111/epi.17241 · Cited by 998
Self-citationPatterns of treatment response in newly diagnosed epilepsy
Brodie, M. J., Barry, S. J. E., Bamagous, G. A., Norrie, J. D., & Kwan, P. (2012) · Neurology · doi:10.1212/wnl.0b013e3182563b19 · Cited by 931
Löscher, W., Potschka, H., Sisodiya, S. M., & Vezzani, A. (2020) · Pharmacological Reviews · doi:10.1124/pr.120.019539 · Cited by 903
Kossoff, E. H., Zupec‐Kania, B. A., Auvin, S., Ballaban‐Gil, K. R., Christina Bergqvist, A. G., Blackford, R., Buchhalter, J. R., Caraballo, R. H., Cross, J. H., Dahlin, M. G., et al. (2018) · Epilepsia Open · doi:10.1002/epi4.12225 · Cited by 768
Self-citationThe epidemiology of drug‐resistant epilepsy: A systematic review and meta‐analysis
Kalilani, L., Sun, X., Pelgrims, B., Noack‐Rink, M., & Villanueva, V. (2018) · Epilepsia · doi:10.1111/epi.14596 · Cited by 587
Surgery for Drug-Resistant Epilepsy in Children
Dwivedi, R., Ramanujam, B., Chandra, P. S., Sapra, S., Gulati, S., Kalaivani, M., Garg, A. K., Bal, C. S., Tripathi, M., Dwivedi, S. N., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1615335 · Cited by 583
Predictors of pharmacoresistant epilepsy
Hitiris, N., Mohanraj, R., Norrie, J., Sills, G. J., & Brodie, M. J. (2007) · Epilepsy Research · doi:10.1016/j.eplepsyres.2007.06.003 · Cited by 527
Cited by
NLRP1 inflammasome in neurodegenerative disorders: From pathology to therapies
Zhang, M.-J., Yang, L., Li, Z.-Y., Zhou, L.-Y., Wang, Y.-J., Wang, H.-S., Cui, X.-J., & Yao, M. (2024) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2024.10.004 · Cited by 21
Metadata
- Authors
- Perucca, E., Perucca, P., White, H. S., & Wirrell, E. C.
- Venue
- The Lancet Neurology
- Publisher
- Elsevier BV
- Published
- 2023-08
- Volume
- 22
- Issue
- 8
- Pages
- 723-734
- ISSN
- 1474-4422 (ISSN-L)
- OpenAlex
- W4381331530
- Cited by
- 305
- References
- 86
- FWCI
- 54.21
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Drug resistance in epilepsy. https://app.cochat.ai/papers/10.1016/s1474-4422(23)00151-5
- The paper
- Perucca, E., Perucca, P., White, H. S., & Wirrell, E. C. (2023). Drug resistance in epilepsy. The Lancet Neurology. https://doi.org/10.1016/s1474-4422(23)00151-5
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.